Clinical Trials | December 05, 2022
Jemperli RUBY phase III trial met its primary endpoint
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
Study achieves primary endpoint of radiographic progression-free survival
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
Subscribe To Our Newsletter & Stay Updated
